Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Calidi Biotherapeutics (CLDI)
NYSE MKT:CLDI
RESEARCH TOOLSreports
Holding CLDI?
Track your performance easily
CLDI Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$0.73 - $18.10
Previous Close$1.36
Volume1.44M
Average Volume (3M)1.55M
Market Cap
$27.33M
Enterprise Value$31.25M
Total Cash (Recent Filing)$1.90M
Total Debt (Recent Filing)$5.33M
Price to Earnings (P/E)―
Beta0.78
Next Earnings
Mar 14, 2025EPS Estimate
-$0.37Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-5.81
Shares Outstanding13,078,022
10 Day Avg. Volume891,855
30 Day Avg. Volume1,551,917
Standard Deviation0.24
R-Squared0.05
Alpha-0.08
Financial Highlights & Ratios
Price to Book (P/B)-1.72
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-1.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-1.30
Forecast
1Y Price Target
$2.50Price Target Upside83.82% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
Calidi Biotherapeutics News
PremiumCompany Announcements
Calidi Biotherapeutics Reveals Promising Virotherapy Data
PremiumCompany Announcements
Calidi Biotherapeutics Advances with FDA Clearance and Funding
Bulls Say, Bears Say
Bulls Say
Clinical SuccessEarly clinical data with a single dose of lead agent CLD-101 showed a near doubling of PFS and OS in some glioma patients.
Potential PartnershipsA partnership related to RTNova may materialize and provide upside to the stock beyond the target price.
Regulatory ApprovalThe FDA has cleared Northwestern University’s IND application for Calidi’s NeuroNova (CLD-101).
Bears Say
Cash ReservesCash on hand is expected to be insufficient, raising concerns about the company's ability to sustain operations.
Financial StabilityThere appears to be a significant risk to the company continuing as a going concern, even after the offering.
Going Concern RiskDespite the recent offering, the company faces notable risks regarding its ability to remain operational.
---
Ownership Overview
12.06% Insiders
0.21% Mutual Funds
1.32% Other Institutional Investors
86.41% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
CLDI FAQ
What was Calidi Biotherapeutics’s price range in the past 12 months?
Calidi Biotherapeutics lowest stock price was $0.73 and its highest was $18.10 in the past 12 months.
What is Calidi Biotherapeutics’s market cap?
Currently, no data Available
When is Calidi Biotherapeutics’s upcoming earnings report date?
Calidi Biotherapeutics’s upcoming earnings report date is Mar 14, 2025 which is in 83 days.
How were Calidi Biotherapeutics’s earnings last quarter?
Calidi Biotherapeutics released its earnings results on Nov 12, 2024. The company reported -$0.65 earnings per share for the quarter, beating the consensus estimate of -$0.856 by $0.206.
Is Calidi Biotherapeutics overvalued?
According to Wall Street analysts Calidi Biotherapeutics’s price is currently Undervalued.
Does Calidi Biotherapeutics pay dividends?
Calidi Biotherapeutics does not currently pay dividends.
What is Calidi Biotherapeutics’s EPS estimate?
Calidi Biotherapeutics’s EPS estimate is -$0.37.
How many shares outstanding does Calidi Biotherapeutics have?
Calidi Biotherapeutics has 18,847,256 shares outstanding.
What happened to Calidi Biotherapeutics’s price movement after its last earnings report?
Calidi Biotherapeutics reported an EPS of -$0.65 in its last earnings report, beating expectations of -$0.856. Following the earnings report the stock price went up 60.19%.
Which hedge fund is a major shareholder of Calidi Biotherapeutics?
Among the largest hedge funds holding Calidi Biotherapeutics’s share is Highbridge Capital Management LLC. It holds Calidi Biotherapeutics’s shares valued at 7K.
---
Calidi Biotherapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$2.50 (83.82% Upside)
$2.50 (83.82% Upside)
Hedge Fund Trend
Decreased
By 9.5K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 6.1%
Last 30 Days ▲ 6.1%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-92.44%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-64.18%
Trailing 12-Months
Company Description
Calidi Biotherapeutics
First Light Acquisition Group Inc is a is a blank check company. It is formed for the purpose of effectuating a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses.
---
CLDI Stock 12 Month Forecast
Average Price Target
$2.50
▲(83.82% Upside)
Technical Analysis
Aditxt, Inc.
―
Intelligent Bio Solutions
―
Plus Therapeutics
―
Virax Biolabs Group Ltd. Class A
―
Best Analysts Covering CLDI
1 Year
1 Year Success Rate
0/3 ratings generated profit
1 Year Average Return
-66.97%
reiterated a buy rating last month
Copying Joel Beatty's trades and holding each position for 1 Year would result in 0.00% of your transactions generating a profit, with an average return of -66.97% per trade.
---